Affordable Access

deepdyve-link
Publisher Website

Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.

Authors
  • Suganya, Sakthivel1, 2
  • Divya, Suresh3, 4
  • Parani, Madasamy4
  • 1 Department of Psychology, TMC Academy, Singapore. , (Singapore)
  • 2 Genome Research Center, Academia Sinica, Taipei City, Taiwan, ROC. , (Taiwan)
  • 3 Department of Pediatrics, National Taiwan University Hospital, Yunlin County, Taiwan, ROC. , (Taiwan)
  • 4 Department of Genetic Engineering, Genomics Laboratory, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India. , (India)
Type
Published Article
Journal
Reviews in medical virology
Publication Date
May 01, 2021
Volume
31
Issue
3
Identifiers
DOI: 10.1002/rmv.2174
PMID: 32965078
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The current pandemic of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has quickly emerged as a global health concern with government bodies worldwide taking drastic control measures. Understanding the virology of SARS-CoV-2, its molecular mechanisms, and its pathogenesis are required for a targeted therapeutic approach. In this review, we highlight the current molecular and drug advances that target SARS-CoV-2 at the genome level. We also summarize studies that therapeutically target the host angiotensin-converting enzyme 2 and proteases. Finally, we summarize antibody-mediated therapeutic approaches, as well as recent trends in vaccine development. Hence, the purpose of this study is to investigate different molecular targets in SARS-CoV-2 pathogenesis and their usefulness in developing strategies for drug development. © 2020 John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times